<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136184</url>
  </required_header>
  <id_info>
    <org_study_id>ION-682884-CS3</org_study_id>
    <secondary_id>2019-001698-10</secondary_id>
    <nct_id>NCT04136184</nct_id>
  </id_info>
  <brief_title>NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy</brief_title>
  <official_title>A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of eplontersen after administration for 65 weeks to&#xD;
      patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as&#xD;
      compared to the NEURO-TTR trial (NCT01737398). For more information, please visit&#xD;
      http://www.neuro-ttransform.com/.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study in up to 140 participants, who will be randomized to&#xD;
      receive subcutaneous (SC) injections of either eplontersen once every 4 weeks or inotersen&#xD;
      once a week. Participants will also receive daily supplemental doses of the recommended daily&#xD;
      allowance of vitamin A. Participants included in the inotersen reference arm will be crossed&#xD;
      over to eplontersen at Week 37 after completing the Week 35 assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mNIS+7 at Week 66</measure>
    <time_frame>Baseline, Week 66</time_frame>
    <description>The mNIS+7 composite score is a measure of neurologic impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function. The mNIS+7 composite score has a range of -22.32 to 346.32, and a higher score indicates lower function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66</measure>
    <time_frame>Baseline, Week 66</time_frame>
    <description>The Norfolk QoL-DN score is a measure of physical function/large fiber neuropathy, symptoms, activities of daily living, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN total score has a range of -4 to 136, and a higher score indicates poorer quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in serum TTR concentration at Week 66</measure>
    <time_frame>Baseline, Week 66</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in serum transthyretin (TTR) concentration at Week 35</measure>
    <time_frame>Baseline, Week 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in modified neuropathy impairment score plus 7 (mNIS+7) at Week 35</measure>
    <time_frame>Baseline, Week 35</time_frame>
    <description>The mNIS+7 composite score is a measure of neurologic impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function. The mNIS+7 Composite Score has a range of -22.32 to 346.32, and a higher score indicates lower function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Norfolk QOL-DN at Week 35</measure>
    <time_frame>Baseline, Week 35</time_frame>
    <description>The Norfolk QoL-DN score is a measure of physical function/large fiber neuropathy, symptoms, activities of daily living, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN total score has a range of -4 to 136, and a higher score indicates poorer quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Neuropathy Symptom and Change (NSC) score at Weeks 35 and 66</measure>
    <time_frame>Baseline, Week 35, Week 66</time_frame>
    <description>NSC score is a questionnaire composed of 38 questions that assess the presence and severity of these neuropathy symptoms (including weakness, loss of temperature and pain sensation, and manifestations associated with autonomic nervous system dysfunction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Physical Component Summary (PCS) score of the 36-Item Short Form Survey (SF-36) at Week 65</measure>
    <time_frame>Baseline, Week 65</time_frame>
    <description>The SF-36 is composed of 8 multi-item scales (35 items) assessing physical function (10 items), role limitations due to physical health problems (4 items), bodily pain (2 items), general health (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items) and emotional well-being (5 items). Each of the 8 scales is scored from 0 to 100 with higher scores indicating better health. The 8 scales can be aggregated into a PCS score, which is also scaled from 0 to 100 with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Polyneuropathy Disability (PND) score at Week 65</measure>
    <time_frame>Baseline, Week 65</time_frame>
    <description>The PND is a 6-stage scoring system: Stage 0: no impairment; Stage 1: sensory disturbances but preserved walking capabilities; Stage 2: impaired walking capacity, but ability to walk without a stick or crutches; Stage 3A/B: walking with help of 1 or 2 sticks or crutches; Stage 4: confined to wheel chair or bedridden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in modified body mass index (mBMI) at Week 65</measure>
    <time_frame>Baseline, Week 65</time_frame>
    <description>mBMI is defined as body mass index in kilograms per square meter (kg/m^2) multiplied by serum albumin in grams per liter (g/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Hereditary Transthyretin-Mediated Amyloid Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Eplontersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplontersen by subcutaneous injection once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inotersen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to Eplontersen administered subcutaneously once every 4 weeks until the end of study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplontersen</intervention_name>
    <description>AKCEA-TTR-LRx IONIS-TTR-LRx</description>
    <arm_group_label>Eplontersen</arm_group_label>
    <arm_group_label>Inotersen</arm_group_label>
    <other_name>ION-682884</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotersen</intervention_name>
    <description>Inotersen by subcutaneous injection</description>
    <arm_group_label>Inotersen</arm_group_label>
    <other_name>TEGSEDI</other_name>
    <other_name>ISIS 420915</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 82 years at the time of informed consent&#xD;
&#xD;
          2. Females must be non-pregnant and non-lactating, and either surgically sterile or&#xD;
             post-menopausal or abstinent&#xD;
&#xD;
          3. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with&#xD;
             a woman of child-bearing potential, the subject or the subject's non-pregnant female&#xD;
             partner must be using a highly effective contraceptive method&#xD;
&#xD;
          4. Diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting&#xD;
             all 3 of the following:&#xD;
&#xD;
               -  Stage 1 or Stage 2 Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage&#xD;
&#xD;
               -  Documented genetic mutation in the TTR gene&#xD;
&#xD;
               -  Symptoms and signs consistent with neuropathy associated with transthyretin&#xD;
                  amyloidosis, including NIS ≥ 10 and ≤ 130&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically-significant (CS) abnormalities in medical history, screening laboratory&#xD;
             results, physical or physical examination that would render a subject unsuitable for&#xD;
             inclusion, including but not limited to abnormal safety labs&#xD;
&#xD;
          2. Karnofsky performance status ≤ 50&#xD;
&#xD;
          3. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease),&#xD;
             including uncontrolled diabetes&#xD;
&#xD;
          4. Prior liver transplant or anticipated liver transplant within 1-yr of Screening&#xD;
&#xD;
          5. New York Heart Association (NYHA) functional classification of ≥ 3&#xD;
&#xD;
          6. Acute coronary syndrome within 6 months of screening or major surgery within 3 months&#xD;
             of Screening&#xD;
&#xD;
          7. Other types of amyloidosis&#xD;
&#xD;
          8. Have any other conditions, which, in the opinion of the Investigator or Sponsor would&#xD;
             make the subject unsuitable for inclusion, or could interfere with the subject&#xD;
             participating in or completing the Study&#xD;
&#xD;
          9. Current treatment with any approved drug for hereditary TTR amyloidosis such as&#xD;
             Vyndaqel® / Vyndamax™ (tafamidis), Tegsedi™ (inotersen), Onpattro™ (patisiran),&#xD;
             off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (TUDCA). If&#xD;
             previously treated with Vyndaqel® / Vyndamax™, diflunisal or doxycycline, and TUDCA,&#xD;
             must have discontinued treatment for at least 2 weeks prior to Study Day 1&#xD;
&#xD;
         10. Previous treatment with Tegsedi™ (Inotersen) or Onpattro™ (patisiran), or other&#xD;
             oligonucleotide or RNA therapeutic (including siRNA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine - Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Neurology Research Office</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3784</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospitals - Neurology Clinic</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autónoma De Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital El Cruce</name>
      <address>
        <city>Florencio Varela</city>
        <state>Buenos Aires</state>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1023AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Fleni</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428 AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perron Institute for Neurological and Translational Science</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurologia de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81210-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurologia de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81210-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas</name>
      <address>
        <city>Campinas</city>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Clementino Fraga Filho</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21941-617</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associação de Assistência à Criança Deficiente - Unidade Lar Escola</name>
      <address>
        <city>São Paulo</city>
        <zip>04032-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cyprus Institute of Neurology and Genetics</name>
      <address>
        <city>Egkomi</city>
        <zip>2371</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile-De-France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion (PAGNI)</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>907 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <state>Guishan District</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>İstanbul Üniversitesi - Istanbul Tıp Fakültesi</name>
      <address>
        <city>İstanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Cyprus</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://www.neuro-ttransform.com/</url>
    <description>NEURO-TTRansform Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyneuropathy</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>ATTR</keyword>
  <keyword>TTR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

